Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2017 - 2020)
Summit Therapeutics' (SMMT) quarterly Non-Current Deferred Tax Liability came in at $2.1 million in Q3 2020, down 3.72% on a QoQ basis from $2.2 million in Q1 2020.
Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2017 - 2020) Analysis & Trends
Summit Therapeutics (SMMT) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $2.1 million in Q3 2020.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $2.1 million (changed N/A YoY) and the FY2019 annual result came in at $2.1 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability declined to $2.1 million in Q3 2020, from $2.2 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.3 million in Q2 2018 to a low of $701273.5 in Q1 2017.
- A 4-year average of $2.2 million and a median of $2.1 million in 2019 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2018 — Non-Current Deferred Tax Liability jumped 357.18% — and 2019, when it plunged 33.03%.
- Tracing SMMT's Non-Current Deferred Tax Liability over 4 years: stood at $701273.5 in 2017, then jumped by 215.9% to $2.2 million in 2018, then retreated by 9.46% to $2.0 million in 2019, then advanced by 5.1% to $2.1 million in 2020.
- The last three Non-Current Deferred Tax Liability figures came in at $2.1 million (Q3 2020), $2.2 million (Q1 2020), and $2.0 million (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 2.11 Mn |
| Sep 30, 2020 | 2.11 Mn |
| Mar 31, 2020 | 2.19 Mn |
| Mar 31, 2020 | 2.19 Mn |
| Dec 31, 2019 | 2.01 Mn |
| Dec 31, 2019 | 2.01 Mn |
| Oct 31, 2019 | 1.96 Mn |
| Oct 31, 2019 | 1.96 Mn |
| Jul 31, 2019 | 2.04 Mn |
| Jul 31, 2019 | 2.04 Mn |
| Jan 31, 2019 | 2.15 Mn |
| Jan 31, 2019 | 2.15 Mn |
| Oct 31, 2018 | 2.22 Mn |
| Oct 31, 2018 | 2.22 Mn |
| Jul 31, 2018 | 2.42 Mn |
| Jul 31, 2018 | 2.42 Mn |
| Apr 30, 2018 | 3.33 Mn |
| Apr 30, 2018 | 3.33 Mn |
| Jan 31, 2018 | 3.21 Mn |
| Jan 31, 2018 | 3.21 Mn |